slbt

Today’s U.S. Stock Market Watch｜#SLBT : The stock is heating up, but the drugs still haven’t entered clinical trials

SLBT has surged hard in recent days, with a 50%+ gain over the past five days. But it’s not a mature pharmaceutical company—it’s more like an early-stage biotech stock that’s just been invited to the market’s “table.” The company only completed a SPAC merger and listed on Nasdaq in June. Its main focus is cell and gene therapies—promising in direction, but still at a very early stage.

In 2025, revenue is about $2.2 million, down 35% year over year. It comes mainly from Taiwan-derived exosome products and plant extract-related offerings; the therapeutic business has not yet generated meaningful revenue. Net loss is approximately $3.82 million. Cash at year-end is about $1.26 million. At the time of listing, it also raised $7.8 million via PIPE financing, which can carry it forward for a while, though it’s not exactly comfortable.

What really matters is whether its CD-19 Armed-T and γδ T cell platforms can advance to regulatory milestones. The company aims to drive Pre-IND and IND-related processes in 2027. If it’s only concept-hot, the stock price can easily ride a short wave; the story only earns the right to continue when the clinical path becomes clearer.

My advice is simple: take a look, don’t chase it with a heavy position. SLBT’s upside comes from its small-cap status, low float, and the imagination around cancer cell therapies. The risks also come from those factors. Next, you can monitor how long the cash burn can last, whether there’s progress toward IND, and whether future financing will dilute shareholders.